+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Alpha Galactosidase"

Fabry Disease Treatment - Global Stategic Business Report - Product Thumbnail Image

Fabry Disease Treatment - Global Stategic Business Report

  • Report
  • April 2025
  • 367 Pages
  • Global
From
Fabry Disease Treatment Market Report 2025 - Product Thumbnail Image

Fabry Disease Treatment Market Report 2025

  • Report
  • April 2025
  • 200 Pages
  • Global
From
From
From
From
From
From
Fabry Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Fabry Disease - Pipeline Insight, 2025

  • Report
  • April 2025
  • 50 Pages
  • Global
From
From
From
  • 13 Results (Page 1 of 1)
Loading Indicator

Alpha-galactosidase is a type of enzyme used to treat endocrine and metabolic disorders. It is used to treat Fabry disease, a rare genetic disorder that affects the body's ability to break down certain fats. Alpha-galactosidase helps break down these fats, allowing them to be eliminated from the body. It is also used to treat other metabolic disorders, such as Gaucher disease, which is caused by an enzyme deficiency. Alpha-galactosidase is available in both oral and injectable forms. Alpha-galactosidase is a relatively new drug in the endocrine and metabolic disorders market. It is used to treat a variety of conditions, including Fabry disease, Gaucher disease, and other metabolic disorders. It is a promising treatment option for these conditions, as it can help reduce symptoms and improve quality of life. Several companies are involved in the Alpha-galactosidase market, including Shire, Sanofi, and Genzyme. These companies produce and market the drug, as well as provide support and resources for patients. Show Less Read more